NORTH CHICAGO, Ill. and
BEIJING, June 1, 2020 /PRNewswire/ -- AbbVie
(NYSE:ABBV), a research-based global biopharmaceutical company, and
Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company,
today announced a global, strategic collaboration to develop and
commercialize SHP2 inhibitors, which
target a key node in cancer and immune cells.
SHP2 is an important protein
mediator of cellular signaling through RAS/MAP kinase pathway. Many
tumors have genetic mutations, driving abnormal cancer cell growth
which relies on SHP2 activity.
SHP2 also plays a key role to control
cytokine production and immune cell response. Therefore, inhibition
of SHP2 is believed to have dual
effects by potentially reducing cancer cell growth and modulating
immune responses to generate anti-tumor activities. Jacobio's early
clinical stage SHP2 assets, JAB-3068
and JAB-3312, are oral small molecules designed to specifically
inhibit SHP2 activity.
"Identifying promising new targeted approaches for solid tumor
patients is a high priority for us," said Mohit Trikha, Ph.D., vice president and head,
early development oncology and Bay Area site head, AbbVie.
"Jacobio's SHP2 program has the
potential to treat cancer patients across many tumor types.
By targeting a key node in both cancer and immune cell signaling
pathways, SHP2 inhibition, both as a
monotherapy and potentially in combination with other agents, may
rapidly advance new treatment options for cancer
patients."
"We are excited to expand our efforts in global development of
delivering breakthrough innovation to not just Chinese, but global
patients with cancer," said Yinxiang Wang, Ph.D., CEO and Chairman,
Jacobio. "We look forward to a productive collaboration with
AbbVie focused on rapidly advancing this novel SHP2 first-in-class therapy as a new approach for
multiple cancer types. I am confident that this partnership will
strengthen our R&D capabilities and ultimately bring benefits
to cancer patients."
Under the terms of the agreement, AbbVie will be granted an
exclusive license to the SHP2
portfolio. Jacobio will continue to conduct early global clinical
trials of JAB-3068 and JAB-3312 with AbbVie covering R&D
expenses. Upon completion, AbbVie will assume global development
and commercialization responsibilities. Jacobio has an option,
exercisable before the initiation of registrational trials, to
exclusively develop and commercialize the SHP2 program in mainland China, Hong
Kong, and Macau. Financial
terms were not disclosed and the transaction is subject to
clearance under the Hart-Scott-Rodino Antitrust Improvements
Act.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Jacobio
Jacobio Pharmaceuticals Co., Ltd. is committed to providing more
products and solutions to people's health. Our mission and
vision are "For Patients" and to develop innovative drugs
globally. The company's R&D centers are located in
Beijing and Boston, with a platform and expertise in
developing allosteric inhibitors against protein tyrosine
phosphatase, KRAS and transcriptional factors. The company is
financed by several top-tier investors, including Lilly Asia
Ventures, Hillhouse, QiMing and BioEngine. For more
information about Jacobio, please visit us at
www.jacobiopharma.com.
View original
content:http://www.prnewswire.com/news-releases/abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors-301068321.html
SOURCE AbbVie